Search research articles

お問い合わせ

JoVEについて

概要リーダーシップブログ JoVEヘルプセンター

著者向け

出版プロセス編集委員会範囲と方針査読よくある質問投稿

図書館員向け

推薦の声購読アクセスリソース図書館諮問委員会よくある質問

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments アーカイブ

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教員リソースセンター教員サイト

プライバシーポリシー

関連する概念動画

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え

Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Same author

Redefining the norms: an interdisciplinary perspective on language testing in multilinguals with acquired and progressive neurogenic disorders.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Same author

MethylCog predicts six-year cognitive ability beyond blood-based ADRD biomarkers.

medRxiv : the preprint server for health sciences·2026

Same author

Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivity.

Alzheimer's research & therapy·2026

Same author

Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.

medRxiv : the preprint server for health sciences·2026

Same author

Development and validation of MethylCog, a blood DNA methylation proxy for cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

関連記事をすべて見る

Search research articles

関連する実験動画

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

バイオマーカー

James E Galvin¹, Michael J Kleiman¹, Paul W Estes²

¹University of Miami Miller School of Medicine, Boca Raton, FL, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association

|December 25, 2025

まとめ

この要約は機械生成です。

新しいコンピューター化された認知テストであるCognivue ClarityとCognivue Amyloid Risk Measure（CARM）を組み合わせることで、アルツハイマー病（AD）の効果的なスクリーニングと、アミロイド陽性である可能性のある個人の特定が可能になります。

キーワード:

アルツハイマー病アミロイド認知機能スクリーニングバイオマーカー

さらに関連する動画

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

関連する実験動画

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

科学分野:

神経学
認知科学
バイオマーカー発見

背景:

アミロイド陽性の早期検出は、アルツハイマー病（AD）およびADによる軽度認知障害（MCI-AD）の診断に不可欠である。
現在のアミロイド陽性検出方法は、高価なバイオマーカーに依存することが多く、診断の遅延や治療または臨床試験の機会の損失につながっている。

主な方法:

Bio-Hermes研究の887人の参加者がCognivue Clarity検査、アミロイドPETスキャン、およびpTau217測定を受けた。
Cognivue Clarityデータから4レベルのCARMを導出するために機械学習アプローチが使用された。
Cognivue Clarityの全体スコアとCARMを組み合わせた2x2スクリーニングパラダイムが作成された。

結論:

10分間のコンピューター化されたテストであるCognivue Clarityは、認知障害を検出し、CARMと組み合わせてアミロイド陽性を予測できる。
Cognivue ClarityとCARMを用いた段階的スクリーニングアプローチは、血漿pTau217が続く可能性があり、早期AD検出のためのコスト効果の高い戦略を提供する。
このアプローチは、高価なPETスキャンを必要とせずに、早期AD治療および臨床試験登録の対象となる個人の特定を強化する。